Background: In the Phase III AURA3 trial (NCT02151981), osimertinib had superior efficacy compared with platinum-based doublet chemotherapy (CT) in patients (pts) with T790M-positive advanced NSCLC, whose disease progressed on or after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy. Here we report the ctDNA genomic profile of pts with T790M-positive advanced NSCLC, whose disease progressed on osimertinib treatment during the AURA3 trial. Methods: Pts with EGFR T790M advanced NSCLC, whose disease had progressed on first-line EGFR-TKI therapy, were randomized 2:1 to osimertinib (80 mg once daily) or platinum-based doublet CT. Paired plasma samples were collected at baseline and following disease progression and/or treatment discontinuation. Plasma samples were analyzed by next generation sequencing (NGS; Guardant Health, Guardant360, 73 gene panel). Results: Among 279 pts randomized to the osimertinib treatment arm, paired plasma samples were available from 83 (30%) pts who had progressed and/or discontinued treatment (PD/DC). 73/83 (88%) pts had baseline detectable ctDNA EGFR mutations (L858R, exon 19 deletion or T790M) and were evaluable for this analysis. Among these 73 pts, 36 (49%) had no detectable T790M at PD/DC, and 11 (15%) acquired EGFR secondary mutation in C797 (C797S n ¼ 10; C797G n ¼ 1). Amplification of MET, HER2, and PIK3CA were detected in 14 (19%), 4 (5%), and 3 (4%) samples, respectively. Other mechanisms of acquired resistance included mutations in BRAF (V600E, n ¼ 3; 4%), KRAS (n ¼ 1; 1%) and PIK3CA (E545K, n ¼ 1; 1%), and oncogenic fusion mutations in FGFR3, RET and NTRK (n ¼ 3; 4%). Conclusions: In this preliminary analysis from AURA3 of paired plasma samples from pts with detectable baseline plasma EGFR mutations and at PD/DC on osimertinib treatment, a diverse mixture of resistance mechanisms were detected, with MET amplification and EGFR C797S most common. No unexpected resistance mechanisms were observed in these second-line osimertinib-treated pts. Understanding resistance mechanisms in the first and second-line settings will help define appropriate combination therapies.
Background: MET mutations leading to exon 14 deletion (METDex14) occur in 3-4% of NSCLCs. Capmatinib is a highly potent and selective MET inhibitor. GEOMETRY mono-1 is a phase II, multi-cohort, multicenter study (NCT02414139) evaluating capmatinib in pts with METDex14 mutated or MET amplified advanced NSCLC. Here we present data from pts with METDex14 mutation who received either 1-2 prior lines of therapy (Cohort 4) or were treatment-naive (Cohort 5b). Methods: Eligible pts were 18 years of age, ECOG PS 0-1 and had ALK and EGFR wt, stage IIIB/IV NSCLC (any histology). Pts with METDex14 mutation (centrally confirmed) were assigned to Cohorts 4 and 5b regardless of MET amplification status/gene copy number and received capmatinib tablets 400 mg twice daily. The primary endpoint was overall response rate (ORR) by BIRC per RECIST v1.1. The key secondary endpoint was duration of response (DOR) by BIRC. Results: As of 9-Aug-2018, 94 pts with METDex14 mutated advanced NSCLC had 18 weeks of follow-up (or discontinued earlier) and were included in this analysis (Cohort 4: 69 of 69 pts in 2 nd or 3 rd line; Cohort 5b: 25 of 28 treatment-naive pts). Treatment was ongoing for 20.3% and 44.0% of pts in Cohorts 4 and 5b, respectively. ORR by BIRC assessment was 39.1% (95% CI, 27.6-51.6) in cohort 4 and 72.0% (95% CI, 50.6-87.9) in cohort 5b. All responses were confirmed. DOR data is not mature with a median duration of follow-up of 5.6 months. Preliminary activity in patients with brain metastases was also observed. The most common AEs ( 20% all grades) across all cohorts (1-6, n ¼ 302), regardless of causality, were peripheral edema (49.0%), nausea (43.4%), vomiting (28.5%), blood creatinine increased (24.5%), dyspnea (24.2%), decreased appetite (21.2%) and fatigue (20.9%). Majority of these AEs was grade 1/2. Conclusions: Capmatinib has demonstrated a clinically meaningful response rate and a manageable toxicity profile in pts with METDex14 mutated NSCLC, particularly in treatment naive pts where the ORR by BIRC is 72%. Differential benefit from 1L to pretreated pts seem to highlight the need for earlier diagnostic testing and prompt treatment of this challenging patient population. 7.0 mo (6.3-7.3) 5.6 mo (4.5-5.9) HR (95% CI; P value) 0.65 (0.54-0.77; <0.0001) a PD-L1 high (TC3 or IC3): Patients with PD-L1 expression in 50% of tumour cells or 10% of tumour-infiltrating immune cells; PD-L1 low (TC1/2 or IC1/2): Patients with PD-L1 expression in 1% and <50% of tumour cells or 1% and <10% of tumour-infiltrating immune cells; and PD-L1 negative (TC0 and IC0): Patients with PD-L1 expression in < 1% of tumour cells and <1% of tumour-infiltrating immune cells. Data cut-off: 15 March 2018. Minimum follow up: 13 months. NCT02367781. DOR, duration of response; HR, hazard ratio; IC, immune cells; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; TC, tumour cells.
